Prograf
Links shared publicly online about this topic
Mylan Receives Approval For Generic Version Of Prograf® Capsules
medicalnewstoday.com — “Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applic” View full resource at medicalnewstoday.com
Most Recently Shared on September 22, 2010 at 5:05 pm By:
MNT Transplants News Health News
Mylan Receives Approval For Generic Version Of Prograf® Capsules http://mnt.to/3K95 #transplants
Prograf approved for combination therapy with mycophenolate mofetil (MMF) in kidney transplant recipients - MPR
empr.com — “The FDA has approved Prograf (tacrolimus, from Astellas) in conjunction with mycophenolate mofetil (MMF) for the prevention of organ rejection in kidney transplant recipients.” View full resource at empr.com
Most Recently Shared on May 28, 2009 at 8:20 pm By:
MPR News: Prograf approved for combination therapy with mycophenolate mofetil (MMF) in kidney transplan.. http://tinyurl.com/mpaqr6
OSAKA Study Results Met Primary Endpoint And Show That Both ADVAGRAF(R) And PROGRAF(TM) Give Similar Results In Renal Transplantation
medicalnewstoday.com — “Astellas Pharma Europe Ltd today announced that the results of the 6-month OSAKA study demonstrate that tacrolimus prolonged release (QD; ADVAGRAF(R), Graceptor(R) in Japan)-based therapy is non” View full resource at medicalnewstoday.com
Most Recently Shared on May 3, 2011 at 8:05 am By:
OSAKA Study Results Met Primary Endpoint And Show That Both ADVAGRAF(R) And PROGRAF(TM) Give Similar Results In Renal ... http://mnt.to/3Vhv
LifeCycle shares soar after low-dose organ rejection drug edges Prograf in Ph3 - FierceBiotech
fiercebiotech.com — “In a head-to-head study with a market leading treatment designed to prevent kidney transplant rejection, Denmark's LifeCycle Pharma says that its once-daily experimental drug edged out Astellas's Read more...” View full resource at fiercebiotech.com
Most Recently Shared on June 21, 2011 at 3:00 pm By:
LifeCycle shares soar after low-dose organ rejection drug edges Prograf in Ph3. http://bit.ly/jZkHTa
Gastro Medical News about Transplantation
mdlinx.com — “Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant Recipients” View full resource at mdlinx.com
Most Recently Shared on June 15, 2010 at 1:30 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf... http://bit.ly/a63v0P #GI
Gastroenterology Article | Transplantation
mdlinx.com — “The Impact of Conversion From Prograf to Generic Tacrolimus in Liver and Kidney Transplant Recipients With Stable Graft Function” View full resource at mdlinx.com
Most Recently Shared on July 3, 2011 at 8:57 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
The Impact of Conversion From Prograf to Generic Tacrolimus in Liver and Kidney Transplant Recipients With S... http://bit.ly/l5y9tt #GI
LifeCycle Pharma Announces Positive Phase III Results: LCP-Tacro™ Trial In Stable Kidney Transplant Patients
medicalnewstoday.com — “LifeCycle Pharma A/S (OMX:LCP) reported that the company's lead product candidate, LCP-Tacro™, successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma” View full resource at medicalnewstoday.com
Most Recently Shared on June 22, 2011 at 7:05 am By:
MNT Clinical Trials Health News
LifeCycle Pharma Announces Positive Phase III Results: LCP-Tacro™ Trial In Stable Kidney Transplant Patients http://mnt.to/3Xv2
Tacrolimus Cleared for Use with MMF in Renal Transplant Patients - Renal and Urology News
renalandurologynews.com — “Astellas Pharma US, in Deerfield, Ill., has received approval for the use of Prograf (tacrolimus) in conjunction with mycophenolate mofetil (MMF) in kidney transplant recipients.” View full resource at renalandurologynews.com
Most Recently Shared on July 23, 2009 at 8:49 pm By:
Renal Urology News Health News, Nephrology, Urology, and Medical Publisher
Tacrolimus Cleared for Use with MMF in Renal Transplant Patients: Astellas Pharma US, in Deerfield, Ill., has re.. http://bit.ly/Nkom8
Watson Laboratories receives FDA approval for Tacrolimus ANDA
news-medical.net — “Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf® capsules.” View full resource at news-medical.net
Most Recently Shared on July 2, 2010 at 1:36 pm By:
Medicare News: Watson Laboratories receives FDA approval for Tacrolimus ANDA: Watson Pharmaceuticals, Inc., today ... http://bit.ly/by9Qwh
Guidelines for care of heart transplant recipients
theheart.org — “They won't be fully published until next year, but the society's top brass gave the world a quick look during its 2010 annual meeting.” View full resource at theheart.org
Most Recently Shared on April 23, 2010 at 3:22 pm By:
ISHLT leaders preview new guidelines for managing heart-transplant recipients: They won't be fully published until... http://bit.ly/9FyZqV
LifeCycle Pharma Announces Positive Results Of Phase 2 Clinical Trial For LCP-Tacro™ In De Novo Liver Transplant Patients
medicalnewstoday.com — “LifeCycle Pharma A/S (OMX: LCP) has announced positive top-line results from a Phase 2 clinical trial involving 58 patients comparing LCP-Tacro™ tablets administered once-daily versus Progra” View full resource at medicalnewstoday.com
Most Recently Shared on January 7, 2011 at 2:05 pm By:
LifeCycle Pharma Announces Positive Results Of Phase 2 Clinical Trial For LCP-Tacro™ In De Novo Liver Transplant... http://mnt.to/3PJT
Watson Pharmaceuticals, Inc. | Investors |
ir.watson.com — “Watson Pharmaceuticals, Inc. | Investors |” View full resource at ir.watson.com
Most Recently Shared on July 2, 2010 at 12:55 pm By:
eyeonfda Health Lawyer and Pharma
Generic Prograf(R) 5 mg Receives FDA Approval http://ow.ly/26eKe
18 Month post-islet cell transplant visit - TuDiabetes
tudiabetes.org — “I just had my 18 month post-transplant visit to Minneapolis. Things are continuing to go well, My A1c was 5.4. My CBC, lipids, and other tests look good so far. I am still waiting on some results. I am still getting used to the Cellcept/Prograf meds. I take them with my meals now which has helped my stomach to feel better, but it is more difficult to keep them stable. I get the levels tested at least monthly, and they are rarely the same. Time is helping, but they are still an issue. I have CMV ” View full resource at tudiabetes.org
Most Recently Shared on January 24, 2010 at 6:43 pm By:
18 Month post-islet cell transplant visit: I just had my 18 month post-transplant visit to Minneapolis. Thin... http://bit.ly/5u9aI9 #dblog
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
MNT Transplants News
The latest transplants news published daily. Articles from research centers, universities and prestigious journals.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
MNT Urology
The latest urology/nephrology news published daily. Articles from research centers, universities and prestigious journals.
Advertisement
